With Revenues From Diabetes And Cardiovascular Portfolio At Risk, Analysts Remain Cautious About Sanofi India
8/27/2014 6:05:22 AM
Sanofi India's recent tie-up with Emcure Pharmaceuticals to jointly market their portfolio of anti-cancer drugs is positive. Although the stock has gained four per cent since, it will be a couple of quarters before the overhang of recent drug pricing policy subsides. Sanofi's stock might remain an underperformer in the near-term.
Unlike its Indian peers such as Sun Pharma and Lupin, up 60-65 per cent, Sanofi's returns have been 19 per cent in the past year. In fact, from mid-July 2014, Sanofi's stock is down about 5.6 per cent due to the new pricing policy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by